The Claim

Among adults without diabetes or cardiovascular disease prescribed GLP-1 receptor agonists for weight management, semaglutide use is associated with a 12% lower risk of developing type 2 diabetes over one year compared to liraglutide use, with the effect becoming statistically significant only after six months of treatment.

Source: Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
67score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

In adults without diabetes or heart disease who are taking GLP-1 receptor agonists to lose weight, those taking semaglutide have a 12% lower incidence of developing type 2 diabetes within one year compared to those taking liraglutide, with the difference becoming detectable only after six months.

See the scientific wording

Among adults without diabetes or cardiovascular disease prescribed GLP-1 receptor agonists for weight management, semaglutide use is associated with an 12% lower risk of developing type 2 diabetes over one year compared to liraglutide use, with the effect becoming statistically significant only after six months of treatment, suggesting a delayed but sustained metabolic advantage.

Why this might work

Semaglutide stays in the body longer and keeps the GLP-1 receptor activated more consistently than liraglutide. This prolonged activation helps the pancreas release more insulin when needed and makes the body’s tissues more responsive to insulin. Over time, this improves blood sugar control and prevents the pancreas from becoming overwhelmed, which stops diabetes from developing.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.

    For people taking weight-loss drugs, semaglutide started to lower diabetes risk only after six months, while liraglutide didn’t show the same benefit—so semaglutide works better over time, but not right away.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.